New Focus in the Fight to Reduce CV Risks in Type 2 Diabetes

At one point, intensive glycemic control was seen as a magic bullet to keep Type 2 diabetes patients from developing cardiovascular disease. That approach faded, however, when VA research cautioned that any benefits of intensive therapy must be weighed against adverse effects such as hypoglycemia and weight gain. Now the focus has shifted to better medication selection, with guidelines suggesting that, for Type 2 diabetes patients who have cardiovascular disease or are at high risk for it, therapy including an SGLT-2 inhibitor or GLP-1 RA should be considered as optimal treatment.

VA TAVR Results Comparable to Outside Care

How do veterans fare when they undergo transcatheter aortic valve replacement with the VA? That was the question asked by a study which sought to examine their association with short- and long-term mortality, length of stay, and rehospitalization within 30 days.

Cardiologist Visits Increase Statin Use at VA

HOUSTON—Statin use remains suboptimal in patients with atherosclerotic cardiovascular disease, according to a VA study trying to find out why. Michael E. DeBakey VAMC researchers and colleagues assessed whether outpatient care with a cardiology provider is associated...